Building its rare disease presence, AstraZeneca has agreed to collaborate with Ionis Pharmaceuticals to develop and commercialise the latter’s Phase III antisense drug, eplontersen. This investigational candidate is being developed for the treatment of transthyretin amyloidosis (ATTR), a rare progressive condition. The deal marks the fourth partnership between the two companies, which have previously entered deals involving Ionis’ antisense therapies.